Free Trial Information
BioCentury | Jul 16, 2007
Product Development

Discontinued agents

...testing for chronic skin ulcers (venous, diabetic and pressure). The compound was later discontinued. (A) Genzyme/Celtrix...
Read More
BioCentury | Nov 13, 2000
Company News

Cell Genesys management update

...Malcolm McKay as VP of quality and regulatory affairs, formerly VP of regulatory affairs at Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Oct 2, 2000
Tools & Techniques

Genzyme, CAT and TGF-beta

...cancer. Companies using TGF-beta as a treatment have met with only partial success. In 1995, Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jul 3, 2000
Company News

Microcide management update

...finance and corporate development and CFO, formerly VP of finance and administration and CFO at Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jun 5, 2000
Finance

Spring loaded

...solid IPO market in the U.S., privately held Insmed "got out" by acquiring publicly held Celtrix...
Read More
BioCentury | Jun 5, 2000
Company News

Celtrix, Insmed Pharmaceuticals deal

...shareholders participating in the company's $34.5 million private placement that closed last week. (Financing, B14). Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jun 1, 2000
Company News

Insmed acquires Celtrix

Insmed completed its previously announced acquisition of CTRX (see BioCentury, Dec. 6, 1999). Insmed will trade on the NASDAQ SmallCap Market under the ticker INSM. Insmed also announced the closure of its $34.5 million equity...
Read More
BioCentury | Apr 10, 2000
Clinical News

SomatoKine IGF-1/BP3 complex regulatory update

...No. 6,040,292 covering the use of SomatoKine to treat Type I and Type II diabetes. Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jan 27, 2000
Financial News

Insmed equity financing

...million in equity financing scheduled to close prior to the completion of its merger with Celtrix...
Read More
BioCentury | Jul 19, 1999
Clinical News

SomatoKine complex of insulin-like growth factor-1 regulatory update

...CTRX received FDA Orphan Drug designation for SomatoKine to treat severe burns. Celtrix Pharmaceuticals Inc. (CTRX), San Jose...
Read More
Items per page:
1 - 10 of 83
BioCentury | Jul 16, 2007
Product Development

Discontinued agents

...testing for chronic skin ulcers (venous, diabetic and pressure). The compound was later discontinued. (A) Genzyme/Celtrix...
Read More
BioCentury | Nov 13, 2000
Company News

Cell Genesys management update

...Malcolm McKay as VP of quality and regulatory affairs, formerly VP of regulatory affairs at Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Oct 2, 2000
Tools & Techniques

Genzyme, CAT and TGF-beta

...cancer. Companies using TGF-beta as a treatment have met with only partial success. In 1995, Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jul 3, 2000
Company News

Microcide management update

...finance and corporate development and CFO, formerly VP of finance and administration and CFO at Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jun 5, 2000
Finance

Spring loaded

...solid IPO market in the U.S., privately held Insmed "got out" by acquiring publicly held Celtrix...
Read More
BioCentury | Jun 5, 2000
Company News

Celtrix, Insmed Pharmaceuticals deal

...shareholders participating in the company's $34.5 million private placement that closed last week. (Financing, B14). Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jun 1, 2000
Company News

Insmed acquires Celtrix

Insmed completed its previously announced acquisition of CTRX (see BioCentury, Dec. 6, 1999). Insmed will trade on the NASDAQ SmallCap Market under the ticker INSM. Insmed also announced the closure of its $34.5 million equity...
Read More
BioCentury | Apr 10, 2000
Clinical News

SomatoKine IGF-1/BP3 complex regulatory update

...No. 6,040,292 covering the use of SomatoKine to treat Type I and Type II diabetes. Celtrix Pharmaceuticals Inc....
Read More
BioCentury | Jan 27, 2000
Financial News

Insmed equity financing

...million in equity financing scheduled to close prior to the completion of its merger with Celtrix...
Read More
BioCentury | Jul 19, 1999
Clinical News

SomatoKine complex of insulin-like growth factor-1 regulatory update

...CTRX received FDA Orphan Drug designation for SomatoKine to treat severe burns. Celtrix Pharmaceuticals Inc. (CTRX), San Jose...
Read More
Items per page:
1 - 10 of 83